ePatientFinder to connect patients to trials, providers with Rep Network partnership

By Melissa Fassbender contact

- Last updated on GMT

ePatientFinder’s Clinical Trial Exchange (CTE) technology platform enables physicians and clinical trial sites to leverage EHR data. (Image: iStock/coscaron)
ePatientFinder’s Clinical Trial Exchange (CTE) technology platform enables physicians and clinical trial sites to leverage EHR data. (Image: iStock/coscaron)
ePatientFinder has signed a two-year agreement with Rep Network through which it will expand clinical trial access across the United States.

ePatientFinder, an EHR-driven clinical trial site optimization and patient identification company, has partnered with Rep Network, a network of more than 2,000 independent sales representatives and distributors.

With a two-sided marketplace and our technology, we can connect chronically ill patients to clinical trials and the network of providers with the Rep Network​,” Tom Dorsett, CEO of ePatientFinder, told Outsourcing-Pharma.com.

According to Dorsett, this allows ePatientfinder to expand its patient-focused network across the country and to implement its patient engagement and trial optimization.

The alliance is a two-year agreement with options to extend the agreement further.

Currently, we are launching in select MSAs [metropolitan statistical areas], with plans to expand nationwide in the near term​,” said Dorsett.

ePatientfinder is always looking at opportunities to create business relationships that will be mutually beneficial and ultimately improve both the clinical trial process and the provider/patient experience​,” he added. 

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers